Igarashi et al., 1999
This typically resolves within the first few weeks on a new dose
661,662 Astrotauopathies result in astrocytes with various morphotypes classified as (i) astrocytic plaques, (ii) tufted astrocytes, (iii) ramified astrocytes, (iv) globular astroglial inclusions, (v) thorn-shaped astrocytes and (vi) granular/fuzzy astrocytes (Fig
Anxiety is not listed as a recognized adverse effect in the FDA prescribing information, and it did not occur at significantly higher rates in treatment groups compared to placebo during pivotal SURMOUNT trials
Novo Nordisk says the US FDA has approved a once daily pill version of Wegovy, described as the first approved pill of its kind The company said trials showed average weight loss of 16.6%, with about a third of roughly 1,300 participants losing 20% or more Novo Nordisk expects a US launch in early January 2026, with investors pushing shares up sharply after the announcement amid strong competition in the weight loss market US regulators have approved an oral version of Wegovy for chronic weight management, giving Novo Nordisk the first daily pill in this drug class cleared for obesity treatment, according to the company and US media reports
The antioxidant enzymes of AsA-GSH pathway help in maintaining ROS homeostasis in cells by avoiding the potential cytotoxicity of ROS and allowing them to function as signal molecules